| Arthritis, Psoriatic
Orencia vs Tremfya
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Orencia vs Tremfya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTremfya has a higher rate of injection site reactions vs Orencia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tremfya but not Orencia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Orencia
Tremfya
At A Glance
SC injection, IV infusion
Weekly (SC) or every 4 weeks (IV)
Selective T-cell costimulation modulator
Subcutaneous / Intravenous
Every 4-8 weeks
Interleukin-23 antagonist
Indications
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Acute GVH disease
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Ulcerative Colitis
- Crohn Disease
Dosing
Rheumatoid Arthritis IV: weight-based (500-1,000 mg) infused over 30 minutes at Weeks 0, 2, and 4, then every 4 weeks; SC: 125 mg once weekly, with optional IV loading dose on Day 1.
Juvenile polyarthritis IV (>=6 yrs): 10 mg/kg (body weight <75 kg) or adult weight-based dose (>=75 kg, max 1,000 mg) at Weeks 0, 2, and 4, then every 4 weeks; SC (>=2 yrs): 50 mg (10 to <25 kg), 87.5 mg (25 to <50 kg), or 125 mg (>=50 kg) once weekly without IV loading dose.
Arthritis, Psoriatic Adult IV: weight-based (500-1,000 mg) over 30 minutes at Weeks 0, 2, and 4, then every 4 weeks; Adult SC: 125 mg once weekly without IV loading dose; Pediatric SC (>=2 yrs): 50 mg (10 to <25 kg), 87.5 mg (25 to <50 kg), or 125 mg (>=50 kg) once weekly.
Acute GVH disease IV: patients >=6 yrs: 10 mg/kg (max 1,000 mg) over 60 minutes on Day -1, then Days 5, 14, and 28 post-transplant; patients 2 to <6 yrs: 15 mg/kg on Day -1, then 12 mg/kg on Days 5, 14, and 28.
Psoriasis vulgaris Adults: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter. Pediatric patients >=6 years and >=40 kg: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.
Arthritis, Psoriatic Adults: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter, alone or with conventional DMARD. Pediatric patients >=6 years and >=40 kg: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter, alone or with conventional DMARD.
Ulcerative Colitis Induction: 200 mg intravenous infusion over at least one hour at Week 0, 4, and 8, or 400 mg subcutaneous injection at Week 0, 4, and 8. Maintenance: 100 mg subcutaneous injection at Week 16 and every 8 weeks thereafter, or 200 mg subcutaneous injection at Week 12 and every 4 weeks thereafter.
Crohn Disease Induction: 200 mg intravenous infusion over at least one hour at Week 0, 4, and 8, or 400 mg subcutaneous injection at Week 0, 4, and 8. Maintenance: 100 mg subcutaneous injection at Week 16 and every 8 weeks thereafter, or 200 mg subcutaneous injection at Week 12 and every 4 weeks thereafter.
Contraindications
—
- History of serious hypersensitivity reaction to guselkumab or to any of the excipients
Adverse Reactions
Most common (>=10%) Headache, nasopharyngitis, upper respiratory tract infection, nausea (RA); in aGVHD: anemia, hypertension, CMV reactivation/infection, pyrexia, pneumonia, epistaxis, CD4 lymphocytes decreased, hypermagnesemia, acute kidney injury.
Serious Serious infections (pneumonia, cellulitis, urinary tract infection, bronchitis, diverticulitis), malignancies (lung cancer, lymphoma), hypersensitivity reactions, acute infusion-related reactions, COPD exacerbation.
Postmarketing Vasculitis (cutaneous and leukocytoclastic), new or worsening psoriasis, non-melanoma skin cancers (basal cell and squamous cell carcinoma), angioedema, fatal anaphylaxis (IV), systemic injection reactions (SC).
Most common (>=1%) Upper respiratory infections (14.3%), headache (4.6%), injection site reactions (4.5%), arthralgia (2.7%), diarrhea (1.6%), gastroenteritis (1.3%), tinea infections (1.1%), herpes simplex infections (1.1%).
Serious Serious infections occurred in <=0.2% in plaque psoriasis trials through Week 16. In ulcerative colitis trials, serious infections occurred in 0.8% with TREMFYA vs. 0% with placebo (44-week trial) and 1.8% vs. 0.7% (24-week trial). In Crohn's disease, serious infections occurred in 1.5% with TREMFYA vs. 0% with placebo.
Postmarketing Hypersensitivity including anaphylaxis, rash.
Pharmacology
Abatacept is a selective T-cell costimulation modulator that inhibits T-lymphocyte activation by binding to CD80 and CD86, thereby blocking the CD28 costimulatory interaction required for full T-cell activation; activated T lymphocytes are implicated in the pathogenesis of RA, pJIA, and PsA.
Guselkumab is a human monoclonal IgG1 lambda antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23) and inhibits its interaction with the IL-23 receptor, thereby inhibiting the release of proinflammatory cytokines and chemokines.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Orencia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Tremfya
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Orencia
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (5/8)
Tremfya
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (5/8) · Qty limit (5/8)
Humana
Orencia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Tremfya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Orencia.
Cost estimate not availableAssistance Fund: Psoriatic Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OrenciaView full Orencia profile
TremfyaView full Tremfya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.